Contravisory Investment Management Inc. Buys New Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Contravisory Investment Management Inc. acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 10,009 shares of the company’s stock, valued at approximately $221,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Stifel Financial Corp lifted its stake in Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the third quarter worth approximately $24,314,000. CWA Asset Management Group LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $3,340,000. Finally, Two Sigma Advisers LP raised its holdings in shares of Teva Pharmaceutical Industries by 15.3% during the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares during the period. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on TEVA. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

Teva Pharmaceutical Industries Stock Down 1.2 %

Shares of NYSE TEVA opened at $21.68 on Friday. The firm has a fifty day simple moving average of $19.14 and a two-hundred day simple moving average of $18.16. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries Limited has a 12 month low of $10.83 and a 12 month high of $22.80.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.